Korean J Hematol.  2008 Sep;43(3):179-183. 10.5045/kjh.2008.43.3.179.

A Case of Desensitization for Hemophilia B Inhibitor Patient with Anaphylaxis to FIX Concentrates

• Park Y
• Yoo KY

• KMID: 2252186
• DOI: http://doi.org/10.5045/kjh.2008.43.3.179

Abstract

Among the patients with hemophilia, 10~15% have hemophilia B, and 1~3% of the hemophilia B patients develop inhibitor to factor IX clotting activity. Allergic reactions to concentrates containing factor IX (FIX) are serious complications during the treatment of hemophilia B patients with inhibitor. Although treatment with recombinant activated factor VII (FVIIa) is generally recommended in these patients, it is limited by the agent's short half-life, a lack of experience with its use in this manner and the prohibitive cost. We report here on a case of a 9-year-old boy with severe hemophilia B with inhibitor and he had a history of anaphylaxis to FIX. The patient was successfully treated with a desensitization protocol with escalating doses of FIX in addition to administering premedications.

Keyword

Hemophilia B; Inhibitor; Anaphylaxis; Desensitization

MeSH Terms

Anaphylaxis
Child
Factor IX
Factor VIIa
Half-Life
Hemophilia A
Hemophilia B
Humans
Hypersensitivity
Factor IX
Factor VIIa

Figure

• 

  Fig. 1 The inhibitor titer during desensitization therapy.

Reference

1). Warrier I. Inhibitors in hemophilia B. Lee CA, Berntorp EE, Hoots WK, editors. Textbook of hemophilia. 1st ed.MA, USA: Blackwell Publishing;2005. p. 97–100.

2). Warrier I. Factor IX inhibitors and anaphylaxis. Rodriguez EC, Lee CA, editors. Inhibitors in patients with haemophilia. 1st ed.MA, USA: Blackwell Publishing;2002. p. 87–91.

3). Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia. 1998. 4:574–6.

4). Shin SA., Kim YD., Lee H. A case of anaphylactic response to factor IX replacement therapy in hemophilia B patient. Korean J Hematol. 2003. 38:188–90.

5). Katz J. Prevalence of FIX inhibitors among patients with hemophilia B: results of a large North America survey. Haemophilia. 1996. 2:28–31.

6). Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol. 1995. 94(Suppl 1):49–52.

7). Sawamoto Y., Shima M., Yamamoto M, et al. Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thromb Res. 1996. 83:279–86.

8). Thorland EC., Drost JB., Lusher JM, et al. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia. 1999. 5:101–5.

9). Warrier I., Ewenstein BM., Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol. 1997. 19:23–7.

10). Dioun AF., Ewenstein BM., Geha RS., Schneider LC. IgE-mediated allergy and desensitization to factor IX in hemophilia B. J Allergy Clin Immunol. 1998. 102:113–7.

11). Shibata M., Shima M., Misu H., Okimoto Y., Giddings JC., Yoshioka A. Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia. 2003. 9:269–71.

12). Curry NS., Misbah SA., Giangrande PL., Keeling DM. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction. Haemophilia. 2007. 13:328–30.

13). Freiburghaus C., Berntorp E., Ekman M., Gunnarsson M., Kjellberg B., Nilsson IM. Tolerance induction using the Malm treatment model 1982-1995. Haemophilia. 1999. 5:32–9.

14). Chuansumrit A., Moonsup Y., Sirachainan N., Benja-ponpitak S., Suebsangad A., Wongwerawattanakoon P. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate. Blood Coagul Fibrinolysis. 2008. 19:208–11.

15). Alexander S., Hopewell S., Hunter S., Chouksey A. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. J Pediatr Hematol Oncol. 2008. 30:93–5.